Healthcare Industry News: osteoarthritis
News Release - September 14, 2009
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial OfficerCHAPEL HILL, N.C.--(HSMN NewsFeed)--POZEN Inc. (NASDAQ:POZN ), a pharmaceutical company focused primarily on products for the treatment of migraine, acute and chronic pain and other pain-related conditions, today announced the appointment of Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer.
Ms. Cermak will be responsible for the development and implementation of POZEN’s commercialization strategy for all of its future product candidates, including the PA family of products. POZEN has previously announced its intention to retain sole ownership of its PA franchise of product candidates while it advances them through Phase 3 and considers how best to commercialize these assets. Ms. Cermak will be responsible for the development of worldwide commercial strategy for these product candidates. She will also be responsible for the management of all current and future strategic alliances for the POZEN portfolio, as well as business development.
Dr. John R. Plachetka, POZEN’s Chairman, President and CEO said, “Hiring an outstanding, multi-talented pharma executive like Liz is a key step in POZEN’s evolution as a company. She has precisely the right experiences and background to help us determine how best we can maximize the value of our PA assets around the world, and all our other products and product candidates, for POZEN shareholders. And, she is the right person to supervise the execution of that strategy. We are most fortunate that she is joining us at this key time.”
Ms. Cermak was employed for twenty-five years at Johnson & Johnson, where she held positions of increasing responsibility at Ortho-McNeil Pharmaceuticals, McNeil Consumer and Specialty Pharmaceuticals and other Johnson and Johnson subsidiaries. She most recently held the position of World-Wide Vice President Personal Products Franchise, Johnson & Johnson Healthcare Products. Her experience spans both prescription and OTC businesses across many therapeutic areas. She specialized in sales and marketing and has managed large and small business units both domestically and outside the US. In addition, she has expertise in business development and finance. She and her husband plan to reside in Chapel Hill.
Ms. Cermak received a BA from Franklin and Marshall College and an MBA from Drexel University.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN’s efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for Treximet(R), which was approved in 2008 by the United States Food and Drug Administration for the acute treatment of migraine attacks, with or without aura, in adults, and with AstraZeneca for VIMOVO(TM), the proposed trade name for the proprietary fixed dose combination of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The Company’s common stock is traded on The NASDAQ Stock Market under the symbol “POZN”. For detailed company information, including copies of this and other press releases, see POZEN’s website: www.pozen.com.
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on GlaxoSmithKline for the sales and marketing of Treximet; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended June 30, 2009. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.